Exhibit 10.3

SECOND AMENDMENT TO EMPLOYMENT AGREEMENT

THIS SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into as of June 15, 2023 (the “Second Amendment Effective Date”) by and between Eric H. Yecies, an individual and resident of the State of New Jersey, (the “Employee”) and LifeMD, Inc. (formerly known as Conversion Labs, Inc.), (the “Company”), a Delaware Corporation. The Employee and the Company are also each hereinafter referred to individually as a “Party” and together as the “Parties”.

RECITALS

WHEREAS, on November 6, 2020 (“Employment Agreement Effective Date”), the Company and the Employee entered into an Employment Agreement (the “Employment Agreement”) whereby Employee was hired to serve the Company in the capacity as General Counsel and Chief Compliance Officer, with a base salary of $270,000 and an equity grant of 200,000 options subject to monthly vesting over a period of 36 months.;

WHEREAS, on or about October 1, 2021, and pursuant to instruction by email from Chief Executive Officer Justin Schreiber, Employee’s annual base Salary was increased to $320,000.

WHEREAS, on January 27, 2022, the Company and the Employee entered into a First Amendment To The Employment Agreement (the “First Amendment”) to: (i) reflect the prior change in base salary to $320,000 per year; (ii) specify a target amount of 40% of the Base Salary for the Performance Bonus; (iii) increase the total equity compensation to include up to 37,500 shares of the Company’s common stock as time-vested Restricted Stock Units (“RSUs”) (of which 25,000 shares have already vested) and up to 105,000 shares of the Company’s common stock as Performance Share Units (“PSUs”), subject to vesting upon the achievement of certain milestones as described in more detail therein; and (iv) add an express indemnification provision and agreement.

WHEREAS, on March 2, 2022, the Company changed Employee’s base salary to $360,000.

WHEREAS, for avoidance of doubt, other than the amendments set forth below in this Second Amendment, all other provisions of the Employment Agreement (as amended by the First Amendment) remain in effect today and moving further, unless and until amended in the future.

WHEREAS, the Parties desire to further amend the Employment Agreement to: (i) cancel the 200,000 stock options previously awarded under Section 4(d) of the Employment Agreement (all of which carry a $7.55 exercise price and are underwater); (ii) accelerate the vesting the remaining 12,500 shares of time-vested RSUs previously awarded under the First Amendment to immediately vest, without restriction, on the Second Amendment Effective Date; (iii) cancel the 105,000 restricted shares previously awarded under the First Amendment (none of which have become earned and vested); and (iv) replace the cancelled awards (from sub-paragraphs (i) and (iii) above) with a new grant of 362,500 shares of restricted stock subject to vesting and other terms as described below.

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Parties hereby agree as follows:

1. Preamble.

a.	The January 27, 2022 grant of 37,500 restricted shares (of which 25,000 shares have already vested) remains effective.
b.	The remaining 12,500 restricted shares hereby immediately vest, without restriction (other than any applicable Rule 144 restriction), on this Second Amendment Effective Date.
c.	Both the 200,000 stock options previously awarded under Section 4(d) of the Employment Agreement and the 105,000 restricted shares previously awarded under the First Amendment are hereby cancelled.

2. Amendments. The Employment Agreement shall be further amended as follows, in accordance with the terms and conditions of Section 8 thereof:

a. Section 4(d) of the Employment Agreement is hereby added:

(d) Replacement of Long-Term Equity Incentive. In exchange for the cancellation of the 200,000 stock options granted under Section 4(d) and the 105,000 RSUs granted under Section 4(f), pursuant to the Company’s 2020 Equity and Incentive Plan (the “Plan”) and any amendments thereto, Employee shall receive, upon the Second Amendment Effective Date, an award of 362,500 restricted shares of the Company’s common stock (“Restricted Shares”) with:

(i) 150,000 restricted shares vesting as follows:

● 12,500 restricted shares immediately vest on the Second Amendment Effective Date;

● 37,500 restricted shares vest on November 20, 2023; and

● 100,000 restricted shares vest on January 1, 2024;

and an additional 225,000 restricted shares vesting upon achievement of the performance and milestones described below:

● 50,000 restricted shares vest upon the healthcare business achieving $100,000,000 in net revenue (defined as gross healthcare sales minus healthcare-related refunds and returns) with a 5% adjusted EBITDA margin, on or before December 31, 2025;

● 50,000 restricted shares vest upon the healthcare business achieving $150,000,000 in net revenue with a 10% adjusted EBITDA margin, on or before December 31, 2026;

● 50,000 restricted shares vest upon the healthcare business achieving $200,000,000 in net revenue with a 10% adjusted EBITDA margin, on or before December 31, 2027;

2

● 37,500 restricted shares vest on 3/1/24 based on the performance of Employee in the 2023 calendar year, at the discretion of the CEO and approval by the Board of Directors; and

● 37,500 restricted shares vest on 3/1/25 based on the performance of Employee in the 2024 calendar year, at the discretion of the CEO and approval by the Board of Directors.

Except as otherwise set forth herein or in the associated Restricted Stock Agreement, vesting of the Restricted Shares will cease upon the termination of Employee’s employment with the Company for cause subject to the terms of the Employment Agreement and any amendments thereto. All Restricted Shares vest immediately and become exercisable in full upon a Change in Control, regardless of whether or not any performance milestone has been met at the time of the Change in Control. As used herein, “Change of Control” means (i) a bona fide transfer or series of related transfers of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used herein, “Group” means any group or syndicate that would be considered a “person” for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. The foregoing grant of Restricted Shares shall be made on the Company’s customary form of restricted stock award for employees. All applicable awards under this Second Amendment shall be subject to forfeiture or other penalties under any clawback or recoupment policy of the Company in effect from time to time.

3. Governing Law; Jurisdiction. This Second Amendment shall be governed by and construed in accordance with the internal laws of the State of New York without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction). Any legal proceeding arising out of or based upon this Second Amendment shall be instituted in the federal courts or the courts of the State of New York and each party irrevocably submits to the exclusive jurisdiction of such courts in any such proceeding.

4. Counterparts. This Second Amendment may be executed in several counterparts, each of which shall be deemed to be an original copy and all of which together shall constitute one agreement binding on all parties hereto, notwithstanding that all the parties shall not have signed the same counterpart.

[signature on next page]

3

IN WITNESS WHEREOF, each of the undersigned hereby (a) executes this Second Amendment to the Employment Agreement provided herein(b) confirms its agreement with the provisions and covenants herein provided; and (c) agrees to be bound by this Second Amendment to the Employment Agreement.

EXECUTED as of the Second Amendment Effective Date, as set forth above.

LIFEMD, INC.
/s/ Justin Schreiber
By:	Justin Schreiber, Chairman & CEO
EMPLOYEE
/s/ Eric H. Yecies
By:	Eric H. Yecies, General Counsel & Chief Compliance Officer

4